Kintor Pharma Announces Completion of First Patient Enrollment in Long-term Safety Phase III Trial of KX-826 for Treatment of AGA

SUZHOU,China,July 19,2023 -- Kintor Pharmaceutical Limited ("Kintor Pharma",HKEX: 9939),a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics,announced thatthe company has initiated the long-term safety trial (the "Long-term Safety Trial") of KX-826,a potential first-in-class androgen receptor (AR) antagonist for the treatment of androgenetic alopecia (AGA) developed in-house,in China and has completed the first patient enrollment today. The Long-term Safety Trial was approved to be conducted by China National Medical Products Administration (NMPA) on 18 April 2023.

The Long-term Safety Trial is a multi-center,open-labelPhase III clinical trial,which involves a total of 16 clinical research centers in China,with Professor Jianzhong Zhang of Peking University People's Hospital as the leading principal investigator (leading PI). A total of 270 male and female AGA patients will be enrolled to evaluate the long-term safety of the topical use of KX-826 for the treatment of AGA patients in China (treatment periodof 52 weeks). The primary endpoint of the trial is theincidence of treatment emergent adverseevents (TEAE). Secondary endpoints include efficacy as measured by the change in target area non-vellus hair count (TAHC) from baseline and other safety indicators.

Previously,Kintor Pharma has successfully completed the Phase II clinical trial for male in China,the Phase IIclinicaltrial for female in China and the Phase IIclinicaltrial for male in the United States for KX-826 in the treatment of AGA. In each trial,after 24-week administration,KX-826 improved hair growth and showed a good safety profile. Most of the adverse events occurred during the study were mild,and similar to placebo,no TEAE resulting inpatient withdrawal from the trial,nor death was reported. The Long-term SafetyTrial will further explore the long-term safety and efficacy of KX-826 in the treatment of AGA on the basis of the safety profile and efficacy of above mentioned trials,which will help provide more data to support the use of such medication for long-term treatment for AGA patients.

About Kintor Pharmaceutical Limited

Kintor Pharmaceutical Limited is developing and commercializing a robust pipeline of innovative small molecule and biological therapeutics for oncology and androgen-receptor-related disease areas with unmet medical needs,including alopecia,acne,COVID-19,prostate cancer,liver and breast cancers. For more information,visit www.kintor.com.cn.